publication venue for
- Erratum to 'Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies' [Cancer Treat. Rev. 58C (2017) 22-33].. 60. 2017
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.. 34. 2008
- Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.. 29. 2003
- Mitoxantrone in acute lymphoblastic leukemia.. 10 Suppl B. 1983
- Gefitinib does not improve survival when combined with gemcitabine and cisplatin in people with advanced non-small-cell lung cancer. 2004
- Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. 2022
- Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. 2022
- Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. 2021
- Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. 2021
- The global landscape of drug development for kidney cancer. 2020
- Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. 2020
- Thymic epithelial tumors: From biology to treatment. 2020
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. 2020
- Improving attribution of adverse events in oncology clinical trials. 2019
- Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 2019
- Challenges and perspectives in the treatment of diabetes associated breast cancer. 2018
- The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. 2018
- Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. 2017
- Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. 2017
- Mantle cell lymphoma - Current standards of care and future directions. 2017
- Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. 2017
- Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. 2017
- Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. 2017
- Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. 2016
- A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. 2016
- Clinical trial designs incorporating predictive biomarkers. 2016
- Clinical characteristics of patients with relapsed multiple myeloma. 2015
- Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. 2014
- Osteosarcoma treatment - where do we stand? A state of the art review. 2013
- Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. 2012
- Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. 2011
- Neuroblastoma: Therapeutic strategies for a clinical enigma. 2010
- Advanced gastric cancer--slow but steady progress. 2010
- Esophagogastric cancer: targeted agents. 2010
- Advances in neoadjuvant therapy for colorectal cancer with liver metastases. 2008
- Oesophageal cancer: new developments in systemic therapy. 2003
- Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. 1999
- Second-line chemotherapy and its evaluation in small cell lung cancer. 1999